Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Author
:
PM Ridker
J Revkin
P Amarenco
R Brunell
M Curto
F Civeira
M Flather
RJ Glynn
J Gregoire
JW Jukema
Y Karpov
JJP Kastelein
W Koenig
A Lorenzatti
P Manga
U Masiukiewicz
M Miller
A Mosterd
J Murin
JC Nicolau
S Nissen
P Ponikowski
RD Santos
PF Schwartz
H Soran
H White
RS Wright
M Vrablik
C Yunis
CL Shear
JC Tardif
Investigators. Outcome
Abstract
:

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk.
Year of Publication
:
2017
Journal
:
The New England journal of medicine
Volume
:
376
Issue
:
16
Number of Pages
:
1527-1539
Date Published
:
2017
ISSN Number
:
0028-4793
URL
:
https://www.nejm.org/doi/10.1056/NEJMoa1701488?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov
DOI
:
10.1056/NEJMoa1701488
Short Title
:
N Engl J Med
Download citation